Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (898) Arrow Down
Filter Results: (898) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,340)
    • People  (4)
    • News  (227)
    • Research  (898)
    • Events  (4)
    • Multimedia  (7)
  • Faculty Publications  (496)

Show Results For

  • All HBS Web  (1,340)
    • People  (4)
    • News  (227)
    • Research  (898)
    • Events  (4)
    • Multimedia  (7)
  • Faculty Publications  (496)
← Page 8 of 898 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • February 2015 (Revised November 2015)
  • Supplement

Building an Integrated Biopharma Company: Crucell (B)

By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling
The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8... View Details
Keywords: Biotechnology; Biopharmacy Company; Licensing Agreements In Biopharmacy; Licensing; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Purchase
Related
Hamermesh, Richard G., Marianne Van Der Steen, and Susan Harmeling. "Building an Integrated Biopharma Company: Crucell (B)." Harvard Business School Supplement 815-086, February 2015. (Revised November 2015.)
  • January 2011 (Revised January 2012)
  • Supplement

The Case of the Unidentified Healthcare Companies2010 (CW)

By: Richard M.J. Bohmer, Ethan S Bernstein, Margarita Krivitski and Srinidhi Reddy
This case presents financial statements and selected rations for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details
Keywords: Financial Statements; Financial Management; Health Care and Treatment; Biotechnology Industry; Health Industry
Citation
Purchase
Related
Bohmer, Richard M.J., Ethan S. Bernstein, Margarita Krivitski, and Srinidhi Reddy. "The Case of the Unidentified Healthcare Companies2010 (CW)." Harvard Business School Spreadsheet Supplement 611-701, January 2011. (Revised January 2012.)
  • January 2011 (Revised January 2012)
  • Case

The Case of the Unidentified Healthcare Companies2010

By: Richard Bohmer, Ethan Bernstein, Margarita Krivitski and Srinidhi Reddy
This case presents financial statements and selected ratios for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details
Keywords: Financial Reporting; Financial Statements; Health Care and Treatment; Health Industry
Citation
Educators
Purchase
Related
Bohmer, Richard, Ethan Bernstein, Margarita Krivitski, and Srinidhi Reddy. "The Case of the Unidentified Healthcare Companies2010." Harvard Business School Case 611-043, January 2011. (Revised January 2012.)
  • September 1993
  • Supplement

Manufacturing at ALZA: The Right Prescription? (B)

By: Dorothy A. Leonard
ALZA, a drug delivery company, must decide what and for whom to manufacture. In the past, it has licensed to pharmaceutical companies its patented system for the slow release of drugs into the human system. Therefore the company has little experience in choice of drug... View Details
Keywords: Experience and Expertise; Decision Choices and Conditions; Patents; Production; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Find at Harvard
Related
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (B)." Harvard Business School Supplement 694-020, September 1993.
  • May 2025 (Revised June 2025)
  • Case

Daiichi Sankyo: Steering a Global Organization

By: Tiona Zuzul, Amy C. Edmondson and Cat Huang
In the spring of 2023, Sunao Manabe, CEO of Daiichi Sankyo, reflected on a pivotal decision. A large Western pharmaceutical company had made a bid to partner with Daiichi Sankyo to develop the next three products in its oncology pipeline. Daiichi Sankyo, a 125-year old... View Details
Keywords: Strategy; Culture Change; Decision-making; Leadership; Culture; Innovation; Psychological Safety
Citation
Educators
Related
Zuzul, Tiona, Amy C. Edmondson, and Cat Huang. "Daiichi Sankyo: Steering a Global Organization." Harvard Business School Case 725-478, May 2025. (Revised June 2025.)
  • May 2014
  • Article

Right Up the Middle: How Israeli Firms Go Global

By: Jonathan Friedrich, Amit Noam and Elie Ofek
The article considers international business enterprises based in Israel and how they successfully expanded from their origins as small businesses. A common technique of those companies in which they focused on market entry in other countries whose markets were too... View Details
Keywords: Globalized Firms and Management; Israel
Citation
Find at Harvard
Read Now
Related
Friedrich, Jonathan, Amit Noam, and Elie Ofek. "Right Up the Middle: How Israeli Firms Go Global." Harvard Business Review 92, no. 5 (May 2014): 113–117.
  • August 2007 (Revised July 2008)
  • Case

HCL Technologies (A)

By: Linda A. Hill, Tarun Khanna and Emily Stecker
When Vineet Nayar became president of HCL Technologies, a global IT services business, in April 2005, he knew the company needed drastic change. Since its founding as a hardware company in the 1970s, HCL had grown into an enterprise with $3.7 billion in revenues and a... View Details
Keywords: Customer Relationship Management; Multinational Firms and Management; Employee Relationship Management; Leading Change; Organizational Change and Adaptation; Competition; Information Technology Industry; Service Industry; India
Citation
Educators
Purchase
Related
Hill, Linda A., Tarun Khanna, and Emily Stecker. "HCL Technologies (A)." Harvard Business School Case 408-004, August 2007. (Revised July 2008.)
  • September 2014 (Revised February 2015)
  • Case

Pfizer and AstraZeneca: Marketing an Acquisition (A)

By: John A. Quelch and James Weber
In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details
Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States
Citation
Educators
Purchase
Related
Quelch, John A., and James Weber. "Pfizer and AstraZeneca: Marketing an Acquisition (A)." Harvard Business School Case 515-007, September 2014. (Revised February 2015.)
  • March 1994 (Revised March 1995)
  • Case

Astra/Merck Group

By: Frank V. Cespedes and Marie Bell
Astra/Merck (A/M), originally a joint venture of AB Astra and Merck & Co., is preparing to be an independent company in 1993. Since the company does not engage in basic research and development of drugs, it is essentially a distribution organization. Fundamental to... View Details
Keywords: Cost vs Benefits; Marketing Strategy; Distribution; Performance Evaluation; Research and Development; Risk and Uncertainty; Sales; Competitive Strategy; Pharmaceutical Industry
Citation
Find at Harvard
Related
Cespedes, Frank V., and Marie Bell. "Astra/Merck Group." Harvard Business School Case 594-045, March 1994. (Revised March 1995.)
  • February 2017
  • Supplement

JCDecaux, 2016: Global Leader ... Again

By: John R. Wells and Gabriel Ellsworth
In 2016, JCDecaux was number one in the world in outdoor advertising. This was a far cry from the situation in 2003; at that time, JCDecaux had been unseated by Clear Channel from the number-one spot that it had held for decades, and it was fighting for second place... View Details
Keywords: JCDecaux; Clear Channel Outdoor; OUTFRONT Media; Lamar Advertising Company; Jean-François Decaux; Jean-Charles Decaux; Outdoor Advertising; Street Furniture; Airports; Billboards; Bicycles; Digital Devices; Digital Marketing; Bidding; Advertising; Advertising Campaigns; Acquisition; Mergers and Acquisitions; Business Growth and Maturation; Business Model; Business Organization; Family Business; For-Profit Firms; Joint Ventures; Design; Price; Profit; Revenue; Geographic Location; Geographic Scope; Global Range; Globalization; Global Strategy; Globalized Firms and Management; Multinational Firms and Management; Globalized Markets and Industries; Government Legislation; Business History; Human Resources; Laws and Statutes; Business or Company Management; Goals and Objectives; Growth and Development Strategy; Growth Management; Marketing; Brands and Branding; Marketing Channels; Marketing Strategy; Product Marketing; Demand and Consumers; Supply and Industry; Operations; Distribution; Infrastructure; Logistics; Product; Product Design; Production; Organizational Structure; Property; Public Ownership; Renting or Rental; Problems and Challenges; Business and Community Relations; Business and Government Relations; Family and Family Relationships; Sales; Situation or Environment; Luxury; Strategy; Business Strategy; Commercialization; Competition; Competitive Advantage; Competitive Strategy; Consolidation; Corporate Strategy; Customization and Personalization; Expansion; Segmentation; Mobile Technology; Wireless Technology; Air Transportation; Bicycle Transportation; Rail Transportation; Transportation Networks; Advertising Industry; France; Paris
Citation
Purchase
Related
Wells, John R., and Gabriel Ellsworth. "JCDecaux, 2016: Global Leader ... Again." Harvard Business School Supplement 717-441, February 2017.
  • Teaching Interest

Global Strategy and Implementation

Professor Vijay Govindarajan

This course focuses on the challenges of developing and implementing strategies in global industries. The aim is to provide students with a conceptual and practical understanding of the strategic and organizational... View Details

  • 03 Apr 2006
  • Research & Ideas

The Competitive Advantage of Global Finance

In the process, he shows how organizations can best equip themselves to take advantage of potential sources of competitive advantage that arise in the global setting. In International Finance: A Casebook, Desai provides case studies on how large View Details
Keywords: by Sean Silverthorne; Financial Services
  • 27 Sep 2006
  • Research & Ideas

Report From Egypt: Studying Global Influences

multinationals that move people across locations, expect frequent travel outside the country, and emphasize abundant training and Web-based process tools. Part of the mission of all three companies in Egypt... View Details
Keywords: by Sean Silverthorne
  • 14 Dec 2020
  • Research & Ideas

What Does December's Drug-Approval Dash Mean for COVID-19 Vaccines?

Pharmaceutical regulators around the world tend to speed through drug applications in December and before major national holidays, according to new research that might raise questions about COVID-19 vaccines and other treatments under... View Details
Keywords: by Danielle Kost; Pharmaceutical; Pharmaceutical
  • February 1986 (Revised November 1992)
  • Case

Novo Industri A/S--1981

By: W. Carl Kester and Glynn Ferguson
This small but rapidly growing Danish biochemical company must choose among several financing opportunities that include a convertible Eurobond, a rights offering in Denmark and an issue of new common shares in the United States. The case involves a broad range of... View Details
Keywords: Capital Markets; Cost of Capital; Bonds; Stock Shares; Financing and Loans; Globalization; Biotechnology Industry; Chemical Industry; Denmark; United States
Citation
Educators
Purchase
Related
Kester, W. Carl, and Glynn Ferguson. "Novo Industri A/S--1981." Harvard Business School Case 286-084, February 1986. (Revised November 1992.)
  • October 2016 (Revised February 2017)
  • Teaching Note

Alvogen

By: Daniel Isenberg, William R. Kerr and Alexis Brownell
Alvogen is an Icelandic pharmaceutical company that makes and sells generic drugs. Founder and CEO Robert Wessman is deciding whether to take on private equity investors willing to buy out all shareholders, merge with a large and publicly-traded US pharmaceutical... View Details
Keywords: Biotechnology; Globalization; Entrepreneurship; Biotechnology Industry
Citation
Purchase
Related
Isenberg, Daniel, William R. Kerr, and Alexis Brownell. "Alvogen." Harvard Business School Teaching Note 817-057, October 2016. (Revised February 2017.)
  • January 2001
  • Case

Abgenix and the XenoMouse

By: Robert J. Dolan
Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to... View Details
Keywords: Product Development; Marketing Strategy; Health Testing and Trials; Risk and Uncertainty; Technological Innovation; Innovation Strategy; Science-Based Business; Biotechnology Industry
Citation
Educators
Purchase
Related
Dolan, Robert J. "Abgenix and the XenoMouse." Harvard Business School Case 501-061, January 2001.
  • September 1995
  • Case

Ares-Serono

By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop
Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational... View Details
Keywords: Geographic Location; Globalized Firms and Management; Asset Management; Balance and Stability; Expansion; Digital Platforms; Leadership Development; Health Care and Treatment; Transformation; Family Business; Problems and Challenges; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland; Europe
Citation
Find at Harvard
Related
Yoshino, Michael Y., Jean-Pierre Jeannet, and Carin-Isabel Knoop. "Ares-Serono." Harvard Business School Case 396-035, September 1995.
  • October 2011 (Revised June 2013)
  • Case

Novo Nordisk: A Commitment to Sustainability

By: Robert G. Eccles and Michael P. Krzus
The case describes the early commitment of a European pharmaceutical company, Novo Nordisk, to integrated reporting. Novo Nordisk is one of the pioneers of integrated reporting and it emerged out of its commitment to a "Triple Bottom Line approach to managing the... View Details
Keywords: Strategic Planning; Business Ventures; Business or Company Management; Integrated Corporate Reporting; Business Strategy; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Eccles, Robert G., and Michael P. Krzus. "Novo Nordisk: A Commitment to Sustainability." Harvard Business School Case 412-053, October 2011. (Revised June 2013.)
  • 13 Nov 2012
  • First Look

First Look: November 13

finds that academic commentary on the BSC often ignores its role in strategy execution. The paper discusses how the BSC can be used in public sector applications, as well as for companies that want to internalize environmental, social,... View Details
Keywords: Sean Silverthorne
  • ←
  • 8
  • 9
  • …
  • 44
  • 45
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.